Skip to content

Study · Animal study (in vivo) · mouse · 2011

9 results

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

Himeno T, Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, Fukami A and 6 more

Show all authors

Hamada Y, Inagaki N, Seino Y, Drucker DJ, Oiso Y, Nakamura J

Diabetes1 Aug 2011Cited by 96 (Europe PMC)

PMID21810596 (opens in a new tab)PMCIDPMC3161330 (opens in a new tab)DOI10.2337/db10-1462 (opens in a new tab)PepBankPUB-21810596
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 did not affect blood glucose.

    In plain wordsIn mice with diabetes, exendin‑4 did not change blood glucose.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBlood glucose
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At the doses used, exendin-4 had no effect on blood glucose or HbA(1c) levels.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 did not affect HbA(1c).

    In plain wordsIn mice with diabetes, exendin‑4 did not change HbA(1c).

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At the doses used, exendin-4 had no effect on blood glucose or HbA(1c) levels.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 improved hypoalgesia.

    In plain wordsIn mice with diabetes, exendin‑4 improved reduced pain sensitivity.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHypoalgesia
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Hypoalgesia and delayed MNCV and SNCV in diabetic mice were improved by exendin-4 without affecting the reduced SNBF.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 improved delayed motor nerve conduction velocity.

    In plain wordsIn mice with diabetes, exendin‑4 improved slow motor nerve conduction.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMotor nerve conduction velocity
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Hypoalgesia and delayed MNCV and SNCV in diabetic mice were improved by exendin-4 without affecting the reduced SNBF.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 improved delayed sensory nerve conduction velocity.

    In plain wordsIn mice with diabetes, exendin‑4 improved slow sensory nerve conduction.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSensory nerve conduction velocity
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Hypoalgesia and delayed MNCV and SNCV in diabetic mice were improved by exendin-4 without affecting the reduced SNBF.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 did not affect reduced sciatic nerve blood flow.

    In plain wordsIn mice with diabetes, exendin‑4 did not change reduced sciatic nerve blood flow.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSciatic nerve blood flow
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Hypoalgesia and delayed MNCV and SNCV in diabetic mice were improved by exendin-4 without affecting the reduced SNBF.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 ameliorated decreased intraepidermal nerve fiber densities in sole skin.

    In plain wordsIn mice with diabetes, exendin‑4 improved reduced nerve fiber density in sole skin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIntraepidermal nerve fiber density
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The decreased IENFDs in sole skins of diabetic mice were ameliorated by exendin-4.
    1 context sentence
    Summary · context
    In animal-model experiments, mice were made diabetic by STZ administration, and after 12 weeks of diabetes, exendin-4 (10 nmol/kg) was intraperitoneally administered once daily for 4 weeks.
  8. 08LabIn vitro (cells)Efficacy outcome

    In cultured mouse DRG neurons, exendin‑4 promoted neurite outgrowth.

    In plain wordsIn cells from mice, exendin‑4 promoted nerve growth.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNeurite outgrowth
    Study

    mousen: not reported in source

    Cultured dorsal root ganglion neurons
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GLP-1 (7-37) and exendin-4 significantly promoted neurite outgrowth of DRG neurons.
    1 context sentence
    Summary · context
    DRG neurons were dissected from C57BL6/J mice and cultured with or without Schwann cell-conditioned media in the presence or absence of GLP-1 (7-37) or exendin-4.
  9. 09LabIn vitro (cells)Efficacy outcome

    In mouse DRG neurons with Schwann cell-conditioned media, exendin‑4 accelerated impaired neurite outgrowth.

    In plain wordsIn cells from mice, exendin‑4 improved impaired nerve growth in media that mimicked diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseImpaired neurite outgrowth
    Study

    mousen: not reported in source

    DRG neurons with Schwann cell-conditioned media
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both GLP-1R agonists accelerated the impaired neurite outgrowth of DRG neurons cultured with Schwann cell-conditioned media that mimicked the diabetic condition.
    1 context sentence
    Summary · context
    DRG neurons were dissected from C57BL6/J mice and cultured with or without Schwann cell-conditioned media in the presence or absence of GLP-1 (7-37) or exendin-4.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.